Latest News
Keep up with the latest at mDETECT
mDETECT Secures $3M seed round to
accelerate commercial rollout of lung cancer
test
April 2026
mDETECT Inc. announces the successful closing of its $3.0 million seed financing round.
The new capital will accelerate the commercialization of mDETECT’s proprietary DNA methylation blood tests, expand clinical validation, and support our upcoming lung cancer test launch that will transform precision cancer monitoring.
Unlike conventional mutation-based blood tests, mDETECT’s liquid biopsy technology targets unique, tumor-specific DNA methylation signatures. By measuring circulating tumor DNA from a simple blood draw, our goal is to provide clinicians with rapid, quantitative insights into treatment response and disease recurrence, months ahead of standard imaging.
mDETECT Ovarian test featured by
Ovarian Cancer Canada
Co-founder Dr. Chris Mueller and his research team at Queen’s University have received funding from Ovarian Cancer Canada to further develop and validate our novel mDETECT-ov liquid biopsy. Designed to identify distinct DNA methylation patterns in the bloodstream, this test aims to detect ovarian cancer earlier and more accurately than traditional methods.
mDETECT featured by Biocreate
mDETECT has been chosen as one of Ontario’s high-potential health-tech startups supported by Ontario Genomics and FedDev Ontario’s BioCreate initiative.
mDETECT wins 1st place at Accelerate OTT
Our Chief Scientific Officer, Keira Frosst won the $25,000 first place prize
at AccelerateOTT with Invest Ottawa. Congrats Keira!
June 2025
mDETECT wins 1st place in pitch
competition
September 2024
Our Co-founder, Dr. Wiginton won the $15,000 USD first place prize
at the LG Innnofest Meeting in San Francisco
mDETECT featured in >75 newspapers across
Canada and interviewed by Global News
mDETECT founder wins 1st place at
pitch competitions
Dr. Wiginton wins first place at the Lab2Market Deep Tech Expo.
Dr. Wiginton receives first place check at the Capital Angel Network's
#MASHUP Event
Read the mDETECT Impact Story featured
by Mitacs
mDETECT secures $900k CIHR grant and
launches breast cancer clinical trial
Join Dr. Wiginton and Dr. Banting discuss
how mDETECT will help cancer patients
In this episode, we interview one of the co-founders of mDetect Inc. - Dr. Irsa Wiginton. Dr. Wiginton holds a PhD in Biochemistry and Cell Biology from Queen's University. mDetect is commercializing a novel 'liquid biopsy' technology to support the treatment of cancer.
Pitch Winners!
Both our founders have been successful in several pitch competitions! Check out some of their stories below.
Congrats to Dr. Mueller for winning second place at the Mitacs Invention to Innovation (i2I) Skills Training Final Pitch Competition.
Congrats to Dr. Wiginton for winning first place at the Kingston Syracuse Pathway Pitch Competition.
New mDETECT blood test helps with earlier
cancer detection and better treatment
June 16, 2021: Queen’s researcher Christopher Mueller has developed a breast cancer
detection test that provides real time response to chemotherapy and early detection of relapse.